Summit Therapeutics Shares Are Trading Higher After the Company Announced That It Received Marketing Authorization in China for Ivonescimab in Combination With Chemotherapy
Summit Therapeutics Shares Are Trading Higher After the Company Announced That It Received Marketing Authorization in China for Ivonescimab in Combination With Chemotherapy
Summit Therapeutics宣佈獲得艾文西單抗聯合化療在中國的上市許可後，該公司股價走高
Summit Therapeutics宣佈獲得艾文西單抗聯合化療在中國的上市許可後，該公司股價走高。此外，該公司宣佈，它接受了一位機構投資者主動提出的以每股9.00美元的價格購買22,222,222股股票的提議，並將把淨收益用於推進艾旺西單抗的臨床開發。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。